Clinical trials: Botulinum Toxins, Type A
Nervous System Disorders
Dysport® Adult Upper Limb Spasticity Extension Study
The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.
- Trial name
- NCT01313312
- Testing
- Botulinum toxin type A
- Where
- 34 sites in United States, Belgium and 7 more
- Volunteers
- 258 people
- Sponsor
- Ipsen
Post-stroke Spasticity of the Upper Limb
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the upper limb are effective in treating spasticity in patients after stroke.
- Trial name
- PURE (NCT01392300)
- Testing
- IncobotulinumtoxinA (400 Units)
- Where
- 47 sites in United States, Czechia and 5 more
- Volunteers
- 317 people
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Lines
Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®
This is an observational study assessing patient satisfaction following at least 5 years of BOTOX® treatment for glabellar lines.
- Trial name
- NCT01608672
- Testing
- botulinum toxin Type A
- Where
- 5 sites in United States, Australia and 3 more
- Volunteers
- 207 people
- Sponsor
- Allergan
Ventral Hernia, Abdominal Hernia
A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique
Ventral hernias form when there is a loss of integrity of the abdominal wall muscles. Abdominal hernias can expand and can cause severe pain as the abdominal wall weakens.
- Trial name
- NCT05606757
- Testing
- BOTOX Dose A, BOTOX Dose B, BOTOX Dose C
- Where
- 2 sites in United States
- Sponsor
- AbbVie
N/A, as no Specific Medical Condition Will be Treated
A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods
The purpose of this study is to evaluate the distribution of IncobotulinumtoxinA (Xeomin) in healthy subjects at different volumes, concentrations and doses when administered intradermally and subcutaneously using different…
- Trial name
- NCT05585398
- Testing
- IncobotulinumtoxinA
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Benign Prostatic Hyperplasia
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
This study will evaluate the safety and efficacy of intraprostatic administration of botulinum toxin Type A (BOTOX®) compared with placebo to treat urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT01107392
- Testing
- botulinum toxin Type A, Normal saline
- Where
- 8 sites in United States, Canada and 6 more
- Volunteers
- 315 people
- Sponsor
- Allergan
Overactive Bladder
Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients
This is a single arm pilot study evaluating the feasibility and preliminary safety of a single intravesical instillation of TC-3 gel mixed with botulinum toxin (BTX) for symptomatic improvement in overactive bladder patients.
- Trial name
- NCT02179099
- Testing
- BTX mixed with TC-3 Gel
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- UroGen Pharma Ltd.
Essential Blepharospasm
Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm
This clinical study evaluates the efficacy and safety of Neuronox compared with Botox in adults with essential blepharospasm.
- Trial name
- NCT03216473
- Testing
- Neuronox, Botox
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Medy-Tox
Overactive Bladder
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
This is a study to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) compared with placebo, in achieving a 100% reduction in urinary incontinence in patients with overactive bladder (OAB) not properly managed with…
- Trial name
- COMFORT (NCT01945489)
- Testing
- onabotulinumtoxinA, Normal saline
- Where
- 40 sites in United States
- Volunteers
- 254 people
- Sponsor
- Allergan
Muscle Spasticity
Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity
This is a prospective, non-interventional, observational study to collect data on the use of botulinum toxin Type A in a routine setting in patients with upper limb adult spasticity.
- Trial name
- NCT01387074
- Testing
- botulinum toxin Type A
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Allergan
Moderate to Severe Glabellar Lines
A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
This is a randomized, double-blind, placebo- and active-controlled parallel-group multi-center phase III study to evaluate the efficacy and safety of Rcombinant botulinum neurotoxin type A for injection (YY001)) in the treatment…
- Trial name
- NCT06499688
- Testing
- Rcombinant botulinum neurotoxin type A for injection (YY001), OnabotulinumtoxinA
- Where
- 16 sites in China
- Volunteers
- 529 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Cervical Dystonia
Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex
This study will compare Xeomin®, a botulinum toxin medication, in shorter treatment intervals (Short Flex dosing) to the standard interval dosing (Long Flex dosing) to determine if the response to treatment is comparable in both…
- Trial name
- NCT01486264
- Testing
- Xeomin®
- Where
- 43 sites in United States
- Volunteers
- 283 people
- Sponsor
- Merz Pharmaceuticals GmbH
Chronic Migraine, Headaches
A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.
- Trial name
- NCT01749410
- Testing
- onabotulinumtoxinA
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Allergan
Urinary Incontinence, Urinary Bladder
OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)
This was a multicenter, randomized, double-blind, parallel-group, multiple-dose study to evaluate the efficacy and safety of BOTOX in adolescents with urinary incontinence due to overactive bladder (OAB) with inadequate…
- Conditions
- Urinary Incontinence, Urinary Bladder, Overactive
- Trial name
- NCT02097121
- Testing
- BOTOX®
- Where
- 39 sites in United States, Australia and 11 more
- Volunteers
- 56 people
- Sponsor
- Allergan
Chronic Migraine
Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
This study will evaluate the use of the Assessment of Chronic Migraine Impacts (ACM-I) Questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxinA (BOTOX®) in adults with chronic migraine.
- Trial name
- NCT01833130
- Testing
- OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Allergan
Overactive Bladder
Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00910845
- Testing
- onabotulinumtoxinA, normal saline
- Where
- 2 sites in United States, Canada
- Volunteers
- 557 people
- Sponsor
- Allergan
Chronic Scar Pain
Dysport in Post-Surgical Neuralgia
The study is designed to determine whether a currently licensed version of botulinum toxin (Dysport®) is effective for the treatment of pain that has developed and/or persisted for months or years around the scar of a previous…
- Trial name
- PMOD03 (NCT03663101)
- Testing
- Lidocaine, Botulinum toxin type A
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Ipsen
Masseter Muscle Prominence
A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants
The masseter muscle is one of the muscles in the lower face used for chewing. Prominence of the masseter muscle can appear as a widened and square lower face shape, which is an aesthetic concern for individuals who prefer a…
- Trial name
- MMP Japan 080 (NCT06137287)
- Testing
- BOTOX
- Where
- 18 sites in Japan
- Volunteers
- 259 people
- Sponsor
- AbbVie
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult…
- Trial name
- CONTENT1 (NCT02660138)
- Testing
- Botulinum toxin type A
- Where
- 81 sites in United States, Canada and 8 more
- Volunteers
- 227 people
- Sponsor
- Ipsen
Glabellar Lines
Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.
To evaluate the efficacy and safety of botulinum toxin type A for injection INI101 compared to BOTOX® in subjects with moderate to severe glabellar lines.
- Trial name
- NCT07622004
- Testing
- Botulinum Toxin Type A Injection [INI101], Botulinum Toxin Type A Injection [Botox]
- Where
- South Korea
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- INIBIO Co., Ltd.